Secondary outcome measures
| Donepezil | Placebo | Treatment effect* | P values | ||
| Means (SEM) | Means (SEM) | Means | (95%CI) | ||
| Psychosis | |||||
| Cx in total PPQ | −0.12 (0.152) | 0.53 (0.166) | −0.652 | (−1.095 to −0.209) | 0.004 |
| Sleepiness | |||||
| Cx in ESS | 0.36(0.45) | 1.69(0.47) | −1.33 | (−2.61to −0.05) | 0.042 |
| Cognitive function | |||||
| Cx in scores of MMSE | 0.02 (0.28) | −0.78 (0.25) | 0.8 | (0.07 to 1.54) | 0.032 |
| Cx in WMS-1 (auditory memory) | 11.2 (1.48) | 7.06 (1.20) | 4.15 | (0.43 to 7.87) | 0.029 |
| Cx in WMS-2 (visual memory) | 3.85 (0.66) | 3.32 (0.80) | 0.53 | (−1.50 to 2.56) | 0.609 |
| Cx in WMS-4 (attention) | 1.02 (0.87) | 0.92 (0.97) | 0.1 | (−2.46 to 2.66) | 0.94 |
| Cx in FAB | 0.07 (0.22) | 0.39 (0.23) | −0.32 | (−0.94 to 0.32) | 0.315 |
Higher scores in PPQand ESS are worse.
Higher scores in MMSE, WMS and FAB are better.
*Effect size was estimated using GEE (working matrix M-dependent).
Cx: changes; ESS, Epworth Sleep Scale; FAB, Frontal Assessment Battery; GEE, generalised estimating equation; MMSE, Mini-Mental State Examination; PPQ,Parkinson’s Psychosis Questionnaire; WMS, Wechsler Memory Scale.